Friday, 2 March 2007
08:50
Welcome and introduction
Pieter E. Postmus, MD, PhD,
Giorgio V. Scagliotti, MD, PhD and
Enriqueta Felip, MD
Session I: State-of-the-art lectures
Chair: Pieter E. Postmus, MD, PhD
09:00
Early diagnosis: Where we are
Speaker Invited
09:20
Systemic therapies in early disease: Are they
worth it for every patient?
Thierry Le Chevalier, MD
09:40
New radiation therapy techniques: Costs and benefits
Suresh Senan, MD
10:00
How many patients with marginally resectable
NSCLC may benefit from surgery?
Paul R. De Leyn, MD, PhD
10:20
Hurdles and benefits of targeted therapies Nicholas Thatcher, MB, BChir, PhD
10:40
Panel discussion
11:10
Coffee break
Session II: Keynote lecture I
Chair: Nico Van Zandwijk, MD, PhD
11:30
Advances in diagnostic imaging
Stefan Schönberg, MD
Session III: Case discussion I
Chair: Pieter E. Postmus, MD, PhD
12:00 Case 1: Second primary
Nico van Zandwijk, MD, PhD
12:30
Case 2: Stage III NSCLC
Wilfried Eberhardt, MD
13:00
Panel discussion
13:20
Lunch break
Session IV: Lung cancer as a genetic disease
Chair: Elisabeth Brambilla, MD
14:30
Molecular pathogenesis of lung cancer
Elisabeth Brambilla, MD
14:50
Genetic predisposition to lung cancer:
Can we identify a high-risk group?
Speaker Invited
15:10
Genetic prognostic and predictive factors
Robert Pirker, MD
15:30
How genes may help us individualize treatment
Giorgio V. Scagliotti, MD, PhD
15:50
Panel discussion
16:10
Coffee break
Session V: Keynote lecture II
Chair: Giorgio V. Scagliotti, MD, PhD
16:30
Targeting the EGFR pathway: The lessons from clinical trials of the last decade
Giuseppe Giaccone, MD, PhD
17:00
Chair summary and take-home messages
Pieter E. Postmus, MD, PhD, Giorgio V. Scagliotti, MD, PhD and Enriqueta Felip, MD
17:10 Adjourn
Saturday, 3 March 2007
Session VI: Parallel meet-the-expert sessions
08:00
Gender-related differences in lung cancer
Enriqueta Felip, MD
Treatment choices in second-line therapy
Lucio Crinó, MD
Frail and elderly patients: Is single-agent
therapy still the only way forward?
Cesare Gridelli, MD
Session VII: Management of tumor and
treatment related symptoms
Chairs: Peter G. Harper, MD and Robert Pirker, MD
09:00
Management of paraneoplastic
syndromes in lung cancer
Giorgio V. Scagliotti, MD, PhD
09:20
Biomarkers and treatment of bone metastases
Peter G. Harper, MD
09:40
Management of the side effects of targeted therapies
Speaker Invited
10:00
Pain control strategies in lung cancer
Robert Pirker, MD
10:20
Panel discussion
10:40
Coffee break
Session VIII: Keynote lecture III
Chair: Pieter E. Postmus, MD, PhD
11:15
Stem cells and lung cancer
Speaker Invited
Session IX: Case discussion II
Chair: Giorgio V. Scagliotti, MD, PhD
11:45
Case 3: Stage II disease with solitary severe
pulmonary emphysema
Wilfried Eberhardt, MD
12:15
Case 4: Limited SCLC with severe COPD
and diabetes type II
Egbert F. Smit, MD, PhD
12:45
Lunch break
Session X: Keynote lecture IV
14:15
Targeting tumor and tumor associated endothelial cells: An integrated approach
Speaker Invited
Session XI: Update on new targets and
new agents in lung cancer
Chairs: Christian Manegold, MD and
Giorgio V. Scagliotti, MD, PhD
14:45
Investigating TLR9 in the treatment of NSCLC
Wilfried Eberhardt, MD
15:05
Enzastaurin and its role in lung cancer therapy
Christian Manegold, MD
15:25
VEGFR inhibitors
Jean-Yves Douillard, MD, PhD
15:45
MTOR inhibitors
Lucio Crinó, MD
16:05
HDAC inhibitors
Johan F. Vansteenkiste, MD, PhD
16:25
Modulators of apoptosis and their role in
lung cancer therapy
Giuseppe Giaccone, MD, PhD
16:45
Panel discussion
17:05
Chair summary and take-home message
Pieter E. Postmus, MD, PhD,
Giorgio V. Scagliotti, MD, PhD
and Rafael Rosell, MD, PhD
17:20
Adjour
©2006 Imedex®, Inc. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.